Top Banner
Overcoming barriers to uptake Aleix Bacardit EMEA Pharmaceuticals & Healthcare Practice London, June 2011
15

Overcoming barriers to uptake Aleix Bacardit EMEA Pharmaceuticals & Healthcare Practice London, June 2011.

Dec 14, 2015

Download

Documents

Jeffery Abrams
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Overcoming barriers to uptake Aleix Bacardit EMEA Pharmaceuticals & Healthcare Practice London, June 2011.

Overcoming barriers to uptake

Aleix BacarditEMEA Pharmaceuticals & Healthcare Practice

London, June 2011

Page 2: Overcoming barriers to uptake Aleix Bacardit EMEA Pharmaceuticals & Healthcare Practice London, June 2011.

A.T. Kearney 2

Mobile Health, What is it?

Mobile phones Patients / Consumers

Connected devicesHealthcare

professionals

Page 3: Overcoming barriers to uptake Aleix Bacardit EMEA Pharmaceuticals & Healthcare Practice London, June 2011.

A.T. Kearney 3

The Mobile Health Promise

Better diagnose and manage

disease

Improve quality of life and

convenience

Better patient data

Consumer & patient education

Improve compliance

Improve administrative

processes

Professional education

Page 4: Overcoming barriers to uptake Aleix Bacardit EMEA Pharmaceuticals & Healthcare Practice London, June 2011.

A.T. Kearney 4

Diabetes illustrates the potential for Mobile to revolutionise health delivery

Source: A.T. Kearney Analysis

Example Type 2 Diabetes Scenario

Targeted local disease awareness marketing

programme

2

Medicine and patient appointment reminders by patient preference channel (SMS, letter,

phonecall)

12

Downloadable profiling tool to identify high risk patients in GP records3

In-practice consultation and blood glucose test. Diagnosis

and patient educated on condition

5

Remote glucose, health and medicines

(online) monitoring

10

Exception reports to GP13

Reminders of monitoring requirements (screening for complications and risk

factors)14

16Patient reward and recognition

programme, e.g. Gym discounts

Week 1 daily patient follow-up using tele-

consultation

9

Diabetes nurse clinic and enrolment and training in

education / support programme

Compilation of personal care plan using down

loadable form

8

7Patient

assigned to MDT including

medicines expert.

Initiation of drugs

4

Out-bound tele-recruitment service to encourage high-

risk patients to present

ILLUSTRATIVE

15Nurse in-home / online / telephone patient

consultation17

Patient monitors cost of care and medicines

11

Medicines delivered

6Patient improves own knowledge

(through interactive online resources)

Practitioners kept up to date with training

and interactive online ‘Q&A discussions’

1

Patients keep in touch through social networking sites

18

1

2

6

10

17

18

3

4

5

7

8

9

15

13

11

12

14

16

EDUCATIONE INTERVENTIONI SUPPORTS

Assessment of mobile health application

Sustained use

Treatment initiation

Seeking treatment

Condition awareness

“Information on conditions”

“Diagnosis & Treatment”

“Overall results management”

High applicability Low applicability

Illustrative

Page 5: Overcoming barriers to uptake Aleix Bacardit EMEA Pharmaceuticals & Healthcare Practice London, June 2011.

A.T. Kearney 5

There is no shortage of problems or solutions

Europe’s top-5

The Health needs are clear Technologies are available

Prevention Awareness Early diagnosis Compliance Managing co-

morbidities Avoiding

unnecessary costs

More phones than people

Hundreds of mobile phone apps

Plenty of devices with connectivity

Note (1): Adults defined as population aged between 20 and 79Various sources. A.T. Kearney analysis

1.3 mobile pp0.4 broadbd /

adult(1)

Europe’s top-5

18m diabetics$57bn

What lies in

between?

Page 6: Overcoming barriers to uptake Aleix Bacardit EMEA Pharmaceuticals & Healthcare Practice London, June 2011.

A.T. Kearney 6

Bridging the gap…Th

e H

ealt

h n

eed

s a

re c

lear

Tech

nolo

gie

s a

re a

vailab

le

Finding the right buyer Making it work commercially Proving Value Integrating (or decommissioning)

services Managing risks and regulation

Page 7: Overcoming barriers to uptake Aleix Bacardit EMEA Pharmaceuticals & Healthcare Practice London, June 2011.

A.T. Kearney 7

Who the buyer depends on boundaries of “health”, and by country and disease

Diagnosed as Ill with a serious disease

Worried Well

More likely to be health systemMore likely to be the consumer

Aspirational Well

Should be Worried Well

Very likely to develop a

serious disease – and

know it

Overweight, Unfit, Smoker, Drinker…

High blood pressure, high cholesterol, obese, low respiratory function,

low liver function…

Atherosclerosis, Diabetes, Renal Failure,

COPD…

Very likely to develop a

serious disease – and Don’t know

Ill with a serious

disease - but not Diagnosed

Page 8: Overcoming barriers to uptake Aleix Bacardit EMEA Pharmaceuticals & Healthcare Practice London, June 2011.

A.T. Kearney 8

Which stakeholder benefits from a Mobile Health solution will depend on how it creates value

“System” Cost/Benefit

Number of

patients

Number

of visits (per

patient)

Number of

activities (per visit)

Cost per

activityx x x=

PopulationRisk Pathway Efficiency

Delivery Efficiency

Page 9: Overcoming barriers to uptake Aleix Bacardit EMEA Pharmaceuticals & Healthcare Practice London, June 2011.

A.T. Kearney 9

Where that value appears depends on the reimbursement system

Where the burden of risk lies in the reimbursement system

Global budget/capitatio

n

Feefor

service

PROVIDER

Risk at the provider side

• Simple, easy to administer

• Excessive (uncontrolled) use of resources

• Efficient use of resources

• Potential for patient selection, under-treatment

A myriad of

systems in

between

Risk at the payer side

PAYER

Page 10: Overcoming barriers to uptake Aleix Bacardit EMEA Pharmaceuticals & Healthcare Practice London, June 2011.

A.T. Kearney 10

Healthcare is an industry driven by evidence, but the evidence for Mobile Health is recognized as being very weak

Source: European Commission: Strategic Intelligence Monitor on Personal Health Systems, 2010; European Commission: ICT and Aging 2010

“Obstacles, however, abound. Among them are […] the lack of clear evidence that mHealth solutions are viable on a wide scale and can deliver real efficiencies”Mobile Health for Independent Living. AARP, 2011

“Evidence of effectiveness is limited and inconsistent, evidence about cost-effectiveness negligible, implementation on wide scale is the challenge”Prof Chris Salisbury, University of Bristol, UK

Page 11: Overcoming barriers to uptake Aleix Bacardit EMEA Pharmaceuticals & Healthcare Practice London, June 2011.

A.T. Kearney 11

What are you trying to prove?

• Superior Outcome, or Non-Inferiority at Lower Cost ?

• Is the research hypothesis clear and realistic?

Do you have the right endpoints and measures?

• Are they relevant to decision makers?

• Is the sample size big enough?

Do you have the right comparator?

• Can you differentiate between the service and the technology?

Is the study method valid?

• What will work best? RCT, observational study, pilot, pre/post analysis?

Common mistakes in gathering evidence

Page 12: Overcoming barriers to uptake Aleix Bacardit EMEA Pharmaceuticals & Healthcare Practice London, June 2011.

A.T. Kearney 12

Mobile Health needs to integrate into the overall care model

• Consultations• Treatment and Medication• Diagnostics and Tests• Rapid response / emergencies• Training • Compliance• Frequency and type of contact with

CM (continuously reviewed)

Care Management Plan

Care Providers

Care Manager

Patient / Carer

Community and Social

Care

Emergency Care

Therapies

Acute Care

Self-CareInformal Care

Joint Decision-Making

Mobile Technologies

Page 13: Overcoming barriers to uptake Aleix Bacardit EMEA Pharmaceuticals & Healthcare Practice London, June 2011.

A.T. Kearney 13

Part of VALUE CHAIN

Commercial services Network Device Value-added services

The more critical the application, the more clinical and regulatory risk comes into play

CriticalLife-critical

interventions

Clinical Risk

Remote monitoring — WELLNESS

Remote monitoring — AMBULANCE

DIAGNOSIS support

UnwellTreatment monitoring

At risk:Diagnosis

Well:Wellness

prevention

Well:Health

information

Content

AdviceData managementMed devicePhone

Encryption

TransmissionBilling

Distribution

Marketing & Sales

Page 14: Overcoming barriers to uptake Aleix Bacardit EMEA Pharmaceuticals & Healthcare Practice London, June 2011.

A.T. Kearney 14

A Prescription to Help Bridge the Gap …

The WorldToday

All of Us, Everywhere

Th

e H

ealt

h n

eed

s a

re c

lear

Tech

nolo

gie

s a

re a

vailab

le

Focus on the service, not the technology. Simple is good

Align the solution with the incentives and financial flows

Define a clear business case, and get the stakeholders to buy into it

Start with applications that don’t require large scale service integration to be successful

Create a plan to build strong evidence that it works

Page 15: Overcoming barriers to uptake Aleix Bacardit EMEA Pharmaceuticals & Healthcare Practice London, June 2011.

A.T. Kearney 15

Thank You

Aleix [email protected]

A.T. Kearney LimitedLansdowne HouseBerkeley SquareLondon W1J 6ER+44 20 7468 8000

Manager+44 20 7468 6800 Direct+44 796716 6800 Mobile